Research Analysts’ Weekly Ratings Changes for Pacira BioSciences (PCRX)

A number of firms have modified their ratings and price targets on shares of Pacira BioSciences (NASDAQ: PCRX) recently:

• 12/1/2025 – Pacira BioSciences had its “sell (d+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/24/2025 – Pacira BioSciences had its “sell (d+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/17/2025 – Pacira BioSciences had its “sell (d+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/17/2025 – Pacira BioSciences had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $38.00 price target on the stock.
• 11/8/2025 – Pacira BioSciences was upgraded by analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating.
• 11/7/2025 – Pacira BioSciences had its price target lowered by analysts at Truist Financial Corporation from $30.00 to $28.00. They now have a “buy” rating on the stock.
• 10/8/2025 – Pacira BioSciences had its “sell (d)” rating reaffirmed by analysts at Weiss Ratings.

Insider Activity at Pacira BioSciences

In other news, insider Jonathan Slonin sold 3,960 shares of the company’s stock in a transaction dated Monday, November 17th. The stock was sold at an average price of $24.09, for a total value of $95,396.40. Following the completion of the sale, the insider owned 178,367 shares of the company’s stock, valued at $4,296,861.03. This represents a 2.17% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 6.40% of the company’s stock.

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.